• the daily intake sufficient to meet the needs of 97.5 % of the population up to the age of 70 (i.e., the recommended daily amount [RDA] ) is 15 μg (600 IU); and • the tolerable upper intake level (TUIL, or simply the UL) is 100 μg/day (4,000 IU/day). (I stress that this is not a limit, but a tolerable level.
The IOM states that it is uncertain about whether there would be any benefits from such an intake but, by specifying 100 μg/day as the UL, it provides explicit assurance that there would be no harm.)
Completeness requires me to note also that, relative to the 1997 dietary reference intakes (DRIs), the IOM panel did produce quite substantial elevations in its recommendations. For adults up to the age of 50, the daily intake recommendation was tripled from 5 to 15 μg (200 to 600 IU); for adults aged 50-70, it was increased from 10 to 15 μg (400 to 600 IU); and for adults aged over 70, it was increased from 15 to 20 μg (600 to 800 IU). Further, in the 1997 DRIs, the UL was 50 μg/day (2,000 IU/day) and it was doubled to 100 μg/day (4,000 IU/day).
There is general agreement that these moves were in the right direction. Still, most working vitamin D scientists have concluded that the IOM did not go far enough, and many of them have publically expressed their dissent from the IOM position both on skeletal and Three lines of evidence converge on the conclusion that 20 ng/ml is not adequate to achieve the skeletal and calcium metabolic benefits of vitamin D. These are:
• randomized controlled trials (RCTs) with fracture endpoints and meta-analyses of such trials;
• physiologic studies of calcium absorption; and
• studies of bone histology with emphasis on osteoid volume. 25 
Anti-fracture Trials
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Studies of Bone Histology
Convergent Evidence
Thus all three lines of evidence converge on the conclusion that a Figure 2 were derived from a study of over 3,500 adults ingesting daily vitamin D doses ranging from zero to 50,000 IU.
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) Once again, as most clinicians have discovered, and as the figure demonstrates, the absolute value of the rise in 25(OH)D in response to a given dose declines as baseline status rises.
What Figure 2 does is to put numbers to this experience.
To apply the information in Figure 2 , note that, for a starting 25(OH)D value close to zero (i.e., 'unmeasurable' in many assays), each 100 IU predicts a rise of about 1.1 ng/ml or, for 600 IU, an aggregate rise of about 7 ng/ml-certainly not 20 ng/ml or higher. In fact, to reach 20 ng/ml requires an all-source, daily input (cutaneous plus oral) averaging about 1,800 IU/day and, to reach 32 ng/ml, the required input averages close to 4,000 IU/day-a figure confirmed in a previously reported, long-duration dose-ranging study.
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Prudential Caution
One possible reason for the surprisingly low recommendations from the IOM is a concern not to do more harm than good. If, for example, the lower end of the normal range had been set at 30, or even 40 ng/ml, and the RDA set at 2,000 IU/day (figures many experts would consider fully justifiable), given the inevitable Gaussian distribution of values, some individuals might conceivably be pushed into a potentially toxic range. That would not be formal vitamin D intoxication to be sure-as the raised UL (4,000 IU/day) assures us-but possibly some of the other ostensible benefits would disappear or unanticipated negative effects would develop. Concern for such unintended outcomes is entirely appropriate and would be expected of such a policy-making body. However, action taken on such concern must depend heavily on the quality of the evidence suggesting untoward effects-in this case, at 25(OH)D concentrations above 40 or 50 ng/ml (specifically cited in the IOM report).
A single study suggesting such harm used 500,000 IU once yearly, and
showed an actual increase in falls and fractures, 29 certainly a concern if applicable. However, it is questionable whether any weight at all should be given to this particular study in view of the fact that, with once yearly concentrations, and has shown why this oscillation nullifies any apparent benefit. 32 Exactly such wide annual oscillation also would have been the case in the study using 500,000 IU once yearly. 29 Vieth noted that annual oscillations of more than a few ng/ml are unphysiologic and described their effect well in advance of the IOM panel's deliberations, but whether the panel was aware of his work is not clear. Inadequate intake of a particular nutrient leads to dysfunction or disease.
This much is a given. To associate a particular nutrient with a particular disease is equivalent to stating that low intake produces or worsens the disease concerned. Such a hypothesis cannot ethically be tested in humans using the RCT design. Even if a particular association turns out not to be causal, the control group in such a trial will have received an inadequate intake and hence will have experienced some disease or dysfunction, if not the one being specifically tested. Continued insistence on RCT-level evidence will guarantee not certainty, but stagnation. n
